Ye jinjun
Quick facts
Phase 3 pipeline
- Sintilimab Combined With Docetaxel Monotherapy · Oncology
Sintilimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: